Vise Technologies Inc. Buys New Stake in Gilead Sciences, Inc. $GILD

Vise Technologies Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 120,100 shares of the biopharmaceutical company’s stock, valued at approximately $15,173,000.

A number of other large investors have also made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $15,393,785,000. Norges Bank acquired a new position in Gilead Sciences during the 4th quarter valued at about $2,617,152,000. Deutsche Bank AG acquired a new position in Gilead Sciences during the 2nd quarter valued at about $918,387,000. Boston Partners purchased a new stake in Gilead Sciences in the fourth quarter valued at about $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Gilead Sciences in the second quarter valued at about $398,905,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Truist Financial decreased their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead’s collaboration with Nucleai highlights a potential strategic shift toward data-driven oncology. Nucleai’s spatial-biology and artificial-intelligence capabilities could help Gilead identify biomarkers, improve patient selection and support its cancer-drug pipeline, although the financial impact remains uncertain. Does Gilead Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?
• Positive Sentiment: BMO Capital reaffirmed its Buy rating, reinforcing the view that Gilead’s HIV franchise, oncology investments and pipeline can support further gains. BMO Capital Reaffirms Buy Rating on Gilead Sciences
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast from a loss of $1.05 to a loss of $0.65 and increased its FY2027 estimate from $9.11 to $9.30. Several quarterly estimates for late 2026 and 2027 were also raised, suggesting improving expectations for future profitability.
• Neutral Sentiment: The recent rally extended to seven consecutive sessions, indicating strong momentum, but the subsequent consolidation may reflect profit-taking as the stock trades near its 52-week high. Gilead Rises for the Seventh Straight Session
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82, equivalent to $3.28 annually and a yield of roughly 2.3%. The payout supports income-oriented investors, though the reported negative payout ratio reflects currently distorted earnings.
• Negative Sentiment: Zacks lowered its FY2028 EPS forecast from $10.00 to $9.58 and cut estimates for Q1 and Q2 2028. Although several nearer-term estimates increased, the mixed revisions signal uncertainty around the longer-term earnings trajectory.
• Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares for approximately $415,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and left him with substantial holdings, making it a limited bearish signal, but insider selling can weigh modestly on sentiment. Gilead Sciences CFO Sells 3,000 Shares

Gilead Sciences Stock Down 2.8%

Shares of GILD stock opened at $143.44 on Friday. The stock’s 50-day simple moving average is $131.56 and its 200-day simple moving average is $136.52. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market capitalization of $177.86 billion, a PE ratio of -53.72 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period last year, the business posted $2.01 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the transaction, the insider owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,000 shares of company stock valued at $10,837,860. 0.30% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.